General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Precision Oncology

Precision oncology accelerates development and improves results

At Novartis Oncology, we are a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes.

Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways:

  • Identify pathways most commonly associated with cancer
  • Screen compounds to identify ones with greatest potential to impact pathway
  • Identify biomarkers and create diagnostic tools
  • Target patients most likely to benefit from therapy
Precision Oncology

Thanks to this approach, the Novartis Oncology Pipeline is one of the strongest and most productive pipelines in the industry. The recent acquisition of the GSK oncology portfolio strengthens our industry-leading pipeline in precision cancer treatment and brings exciting potential to the development of combination regimens.

Together, we discover innovative medicines that help improve the lives of cancer patients.